Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TIAN YUAN HEALTHCARE

天 元 医 疗

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED

中 國 天 元 醫 療 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 557)

REQUEST FOR REVIEW OF THE DECISION OF THE STOCK EXCHANGE ON RULE 13.24 OF THE LISTING RULES

This announcement is made by China Tian Yuan Healthcare Group Limited (the "**Company**") pursuant to Rule 13.09 of the Rules (the "**Listing Rules**") Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 23 November 2026 (the "**Decision Announcement**") in relation to the decision of the Stock Exchange dated 20 November 2026 (the "**Decision**") that the Company has failed to maintain a sufficient level of operations and assets of sufficient value to support its operations to warrant the continued listing of its shares under Rule 13.24 of the Listing Rules, and that trading in the Company's shares will be suspended under the Listing Rules, unless the Company applies for a review of the Decision.

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company and potential investors that, on 27 November 2026, the Company submitted a written request for the Decision to be referred to the Listing Committee of the Stock Exchange for review (the "**Review**") pursuant to Rule 2B.06(1) of the Listing Rules. Pending the Review, unless the Company withdraws its application, trading of the Company's shares will continue.

Shareholders and potential investors are reminded that the outcome of the Review is uncertain. Should the Listing Committee of the Stock Exchange uphold the Decision after the Review, or should the Company withdraw its application for the Review, trading in the Company's shares may be suspended under Rule 6.01(3) of the Listing Rules.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules.

Shareholders who have any queries about the implications of the Decision are advised to obtain appropriate professional advice. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China Tian Yuan Healthcare Group Limited
Dong Wei
Executive Director

Hong Kong, 27 November 2026

As at the date of this announcement, the Board is comprised of five Directors of which Ms. Dong Wei is the executive Director; Ms. He Mei is the non-executive Director; and Mr. Yuen Kwok Kuen, Ms. Zhou Siqi and Mr. Li Jun are the independent non-executive Directors.